Compare NVS & MUFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVS | MUFG |
|---|---|---|
| Founded | 1895 | 1880 |
| Country | Switzerland | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7B | 268.9B |
| IPO Year | 2001 | 2002 |
| Metric | NVS | MUFG |
|---|---|---|
| Price | $144.85 | $22.95 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $144.00 | N/A |
| AVG Volume (30 Days) | 2.4M | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | 2.16% | ★ 2.32% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.30 | $4.62 |
| Revenue Next Year | $5.27 | $10.12 |
| P/E Ratio | ★ $23.13 | $25.47 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $121.57 | $14.65 |
| 52 Week High | $170.46 | $24.26 |
| Indicator | NVS | MUFG |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 49.04 |
| Support Level | $142.26 | $21.50 |
| Resistance Level | $146.35 | $23.11 |
| Average True Range (ATR) | 1.87 | 0.32 |
| MACD | 0.85 | -0.09 |
| Stochastic Oscillator | 77.00 | 36.10 |
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.